

CURRICULUM VITAE

JACK OWENS SIPPERLEY, M.D.

OFFICE LOCATIONS:

Retinal Consultants of AZ, Ltd.
1101 East Missouri Avenue
Phoenix, AZ 85014
602-222-2221

Retinal Consultants of AZ, Ltd.
2152 S. Vineyard, Bldg. 12, Suite 139
Mesa, AZ 85210
480-833-7898

Retinal Consultants of AZ, Ltd.
10615 W. Thunderbird, #D-500
Sun City, AZ 85351
623-972-1173

1. EDUCATION:

Undergraduate:

Florida State University
Biology Major
Bachelor of Science, June 1967

Professional Education:

University of Miami School of Medicine
M.D. Degree, June 1971

Post Graduate:

Jackson Memorial Hospital
Miami, Florida
Internship: Internal Medicine
June 1971- June 1972

Bascom Palmer Eye Institute
Miami, Florida
Resident: Ophthalmology
July 1975 - June 1978

Chief Resident: Ophthalmology
July 1978 - December 1978

Fellowship: Medical Retina
Donald M. Gass, M.D.
July 1978 - May 1979

Duke University
Durham, North Carolina
Fellowship: Vitreoretinal Diseases & Surgery
May 1979 - August 1979

2. BOARD CERTIFICATION:

Specialty Boards:

American Board of Ophthalmology, October 1979

Professional Licenser:

Florida	#24569	June 1971
Georgia	#14566	June 1972

North Carolina	#23436	June 1979
Texas	#F6113	December 1979
Oregon	#	August 1983
Arizona	#16167	May 1986
Colorado	#31094	June 1991

3. MILITARY ASSIGNMENTS:

University of Miami School of Medicine
Miami, Florida, September 1967 - June 1971

Jackson Memorial Hospital
Miami, Florida, June 1971 - June 1972

Royal Air Force Lakenheath
Lakenheath, England
General Medicine Officer
August 1972 - June 1975

Bascom Palmer Eye Institute
Miami, Florida, July 1975 - May 1979

Duke University
Durham, North Carolina, May 1979 - August 1979

Wilford Hall United States Air Force Medical Center
Department of Ophthalmology, August 1979 - July 1983

4. ACADEMIC APPOINTMENTS:

Addenbrooke's Hospital, Cambridge, England
Clinical Instructor, Department of Ophthalmology
August 1973 - June 1975

Wilford Hall United States Air Force Medical Center
Staff Ophthalmologist, Chief, Retina Service
August 1979 - July 1980
Staff Ophthalmic Pathologist
August 1979 - June 1983
Vice Chairman, Resident Program Coordinator
July 1980 - June 1982
Chairman, Department of Ophthalmology
June 1982 - June 1983

University of Texas Health Science Center
Clinical Assistant Professor
August 1979 - July 1980
Clinical Associate Professor
July 1980 - June 1983

Audy Murphy Veterans Administration Hospital

San Antonio, Texas
Consultant Department of Ophthalmology
July 1979 - June 1983

University of Oregon Health Science Center
Portland, Oregon
Clinical Assistant Professor
Staff Ophthalmologist, Chief Retina Service
June 1983 - June 1986

Good Samaritan Hospital & Medical Center
Portland, Oregon
Director of Ophthalmology Research
June 1983 - June 1986

Mayo Medical School, Scottsdale, AZ
Assistant Professor of Ophthalmology
April 1999 - present

Veterans Administration Hospital
Phoenix, Arizona
Retina Consultant
August 1986 - Present

5. MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS:

American Academy of Ophthalmology
San Antonio Ophthalmologic Society
Association of University Professors of Ophthalmology
Society of Air Force Clinical Surgeons
Society of Military Ophthalmologists
Bascom Palmer Alumni Association
University of Miami School of Medicine Alumni Association
Air Force Association
American Medical Association
Oregon Academy of Ophthalmology, Executive Committee
Multnomah County Medical Society
Arizona Medical Association
Arizona Ophthalmologic Society
Maricopa County Medical Society
Phoenix Ophthalmologic Society
American Society of Retina & Vitreous Surgeons
European Retina & Vitreous Society

6. PROFESSIONAL HONOR/EXECUTIVE POSITIONS HELD:

Lang Book Award, 1971

Iron Arrow, University of Miami, 1971

Honor Award, American Academy of Ophthalmology, 1991

7. Research Trials:
ETDRS: Early Treatment Diabetic Retinopathy Study, 1984-1985, Co-investigator
- MPS: Macular Photogulation Study, 1983 -1985, Co-investigator
- DRVS: Diabetic retinopathy Vitrectomy Study, 1984-1985, CCo-investigator
- Sorbinil Trail for treatment of Diabetic Retinopathy, 1983-1985, Principal Investigator
- SST: Submacular Surgery Trials.* National Eye Institute, 1999-2006. Principal Investigator
- Multicenter, Randomized, Double Masked, Controlled Study to Evaluate the Safety and Efficacy of an Intravitreal Implant in Patients with Non-Infectious Uveitis Affecting the Posterior Segment of the Eye. Protocol 415-001.* Bausch and Lomb, 2000-2006, Sub-Investigator
- BLD: Basal Lamina Drusen.* National Eye Institute, 2001-present. Referring Physician.
- CAPT: Complications of Age-Related Macular Degeneration Prevention Trial.. National Eye Institute, 2001-present. Referring Physician.
- Protocol B7A-MC-MBCM.* Eli Lilly, 2001-present. Sub-Investigator.
- A Phase II/III, Randomized, Double Masked, Controlled, Dose-Ranging, Multi-Center, Comparative Trial in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injection of Macugen. Given Every Six Weeks in Patients with Exudative Age Related Macular Degeneration. Protocol EOP1004C. Sub-Investigator.
- A Multi-Center, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of an Implant, in the Treatment of Patients with Diabetic Macular Edema. Protocol CDS FL-007. Control Delivery Systems, 2001-2006, Sub-Investigator.
- A Multi-Center, Randomized, Masked, Controlled Study to Evaluate an Intravitreal Implant in Patients with Diabetic Macular Edema. Protocol CDS FL-005. Control Delivery Systems, 2001-2006, Sub-Investigator
- A Phase II, Randomized, Multi-Center, Dose-Ranging, Controlled Parallel Group Trial to Assess Safety and Efficacy of a Posterior Segment Drug Delivery System in the Treatment of Persistent Macular Edema. Protocol DC103-06-02. Oculex, 2001-2002, Sub-Investigator
- A Phase II, Randomized, Masked, Single and Multiple Dose, Sequential Dose-Escalation Study of the Safety and Efficacy of Subjects with Subfoveal Choroidal Neovascularization Associated with Age Related Macular Degeneration. Protocol A4321001. Pfizer, 2004-2006, Sub-Investigator
- A Phase I/II, Single-Masked, Multi-Center Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections in Combination with Verteporfin (Visudyne) Photodynamic Therapy in Subjects with Neovascular Age-Related Macular Degeneration. Protocol FVF2428g. Genentech, 2003-present, Principal Investigator
- A Phase III, Multi-Center, Randomized, Double-Masked, Sham injection-Controlled Study of the Efficacy and Safety of Subjects with Minimally Classic or Occult Subfoveal Neovascular Age Related Macular Degeneration. Protocol FVF2598g. Genentech, 2003-present, Sub-Investigator
- A Six-Month, Phase III, Multi-Center, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open Label Extension) to Assess to Safety and Efficacy of 700µg and 350µg Posterior Segment Drug Delivery System Applicator System in the Treatment of Patients with Macular Edema Following Central Vein Occlusion or Branch Retinal Vein Occlusion. Protocol 206207-009.-00. Allergan, 2004-present, Sub-Investigator

A Phase II, Multi-Center, Randomized, Masked, Controlled, Study of the Effects of study medication in Combination with Visudyne in Patients with Subfoveal Choroidal Neovascularization Associated with Age Related Macular Degeneration. Protocol MSI-126F-208. Genaera, 2004-2006. Sub-Investigator

A Phase II, Multi-Center, Randomized, Masked, Controlled Study for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age Related Macular Degeneration. Protocol MSI-126F-209. Genaera, 2004-2006, Sub-Investigator

A Phase II, Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups to Determine the Safety, Efficacy and Pharmacokinetics of Intravitreal Injections Compared to Sham Injections for 30 Weeks in Patients with Recent Vision Loss Due to Macular Edema Secondary to CRVO. Protocol EOP1011C. Eyetech, 2004-2006, Sub-Investigator

An Evaluation of Efficacy and Safety of Posterior Juxtasclear Administrations of study medication for Depot Suspension (15mg or 30mg) Versus Sham Administration in Patients (Enrolled in Study "A" or Study "B") at Risk for Developing Sight-Threatening Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration. Protocol C-02-60. Alcon, 2004-present, Sub-Investigator

A Phase IIIB/IV, Randomized, Active Controlled, Double-Masked, Single Dummy, Multi-Center Study Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections Given Every 6 Weeks for up to 102 Weeks Plus Sham Photodynamic Therapy (PDT), to study medication Plus PDT With study medication, in Subjects with Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). Protocol EOP1012C. Eyetech Pharmaceuticals, Inc., 2005 – 2006, Sub-Investigator

A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration. Protocol ACU-201. Acuity Pharmaceuticals, 2005 – 2006, Sub-Investigator

A Phase II, Pharmacokinetic, Randomized, Double-Masked, Controlled, Dose Comparison Study for Intravitreal Injection for the Treatment of Diabetic Macular Edema. Protocol ACU211. Acuity Pharmaceuticals, 2005 – 2006, Sub-Investigator

A Phase IIIB, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of study medication in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). Protocol FVF3689g. Genentech, 2005 – present, Sub-Investigator

An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability in Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Who Have Completed the Treatment Phase of a Genentech-Sponsored Study. Protocol FVF3426g. Genentech, 2005 – present, Principal Investigator

A Prospective, Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Tolerability of Two Dose Levels of the Implant In Diabetic Macular Edema. Protocol HITI-001. SurModics, Inc., 2005 – present, Sub-Investigator

An Evaluation of Efficacy and Safety of study medication combined with Transpupillary Thermotherapy (TTT) in Patients with Subfoveal Exudative Age Related Macular Degeneration (AMD). Protocol 2005-0553. Retinal Consultants of Arizona, Ltd., 2005 – 2006, Sub-Investigator

Study medication for the Treatment of Serous Pigment Epithelial Detachments due to Age-Related Macular Degeneration. Protocol FVF3538s. Retinal Consultants of Arizona, Ltd., 2006 – present, Sub-Investigator

A Randomized, Double-Masked, Parallel Group, Multicenter, Dose-Finding Comparison of the Safety and Efficacy of 0.5µg/day and 0.2µg/day to Sham Injection In Subjects with Diabetic Macular Edema. Protocol C-01-05-001. Alimera Sciences, Inc. and pSivida Inc., 2006 – present, Sub-Investigator

A Phase I, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of MS-R001 in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy. Protocol DR-001.00. MacuSight, Inc., 2006 – present, Sub-Investigator

A 2-Year, Multicenter, Randomized, Controlled, Masked, Dose-Finding Trial to Assess the Safety and Efficacy of Multiple Intravitreal Injections in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Protocol 211745-001-00. Allergan, 2006 – present, Sub-Investigator

Study medication for Edema of the Macula in Diabetes: A Phase 2 Study. Protocol READ-2. Johns Hopkins University, 2006 – present, Sub-Investigator

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel Group Evaluation of the Safety and Efficacy of Ophthalmic Solution to Prevent Formation or Delay Progression of Nuclear Cataract Formation in Post-Vitrectomy Patients. Protocol OT-551-002. Othera Pharmaceuticals, Inc., 2006 – present, Sub-Investigator

RHEO-AMD, Safety and Effectiveness in a Multi-center, Randomized, Sham-controlled Investigation for Age-Related Macular Degeneration (AMD) Using the Rheophoresis Treatment. Protocol RHEO-AMD 01-06. OccuLogix, Inc., 2006 – present

A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of Patients with Neovascular Age-Related Macular Degeneration. Protocol VGFT-OD-0508. Regeneron, 2007 – present Sub-Investigator

Open Label Treatment for Patients Completing Study B7A-MC-MBCM. Protocol B7A-MC-MBDV. Eli Lilly and Company, 2007 - present Sub-Investigator

A Double-Masked, Placebo-Controlled, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Uveitis. Protocol LX211-01-UV. Lux Biosciences, Inc., 2006 – present Sub-Investigator

Double-Masked, Placebo-Controlled, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Quiescent Sight Threatening, Non-Infectious Uveitis. Protocol LX211-02-UV. Lux Biosciences, Inc., 2006 – present Sub-Investigator

Double-Masked, Placebo-Controlled, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Uveitis. Protocol LX211-03-UV. Lux Biosciences, Inc., 2006 – present Sub-Investigator

8. RESEARCH GRANTS:

NO1-EY-6-2141: Clinical Trial to Evaluate Early Vitrectomy in Diabetic Retinopathy, Co-investigator

NO-EY-7-244: Controlled Clinical Trial to Evaluate the Early Treatment of Diabetic Retinopathy, Co-investigator

IND 14-024: Multi-clinic Study of the Effects of Sorbinil Compared to Placebo on the Development of Diabetic Retinopathy and Neuropathy, Protocol B, Protocol 039-01, Principal Investigator, July 1984 - June 1986

5VIOEY 11547-04: Submacular Surgery Trails – Multi-Center Study, Principal Investigator, March 1999-Sept. 2005

BPD OCR 005: Open-Label, Multi-Center, Safety Study of the Treatment of Predominantly Classic Subfoveal Choroid Neovascularization (CNV) Secondary to Age Related Macular Degeneration (AMD) using Photodynamic Therapy with Vertoporphin for Injection. Co-Investigator, Sept. 01, 1999 – April 12, 2000

BLP 415-001: A Multi-Center Study to Evaluate the Safety and Efficacy of an Intravitreal Fluocinolone Acetonide Implant in Patients with Non Infectious Uveitis Affecting the Posterior Segment of the Eye, Co-Investigator, December 01, 2000 -

9. PUBLICATIONS:

"Short-term Effect of Intraocular Pressure Elevation on the Human Electrogram," Jack O. Sipperley, M.D., D.R. Anderson, M.D., D. Hamasaki, Archives of Ophthalmology, Vol. 90, November 1973.

"Small Melanomas of the Choroid," C.C. Barr, M.D., J. O. Sipperley, M.D., D. H. Nicholson, M.D., Archives of Ophthalmology, Vol. 16, September 1978.

"Traumatic Retinopathy in Primates," J. O. Sipperley, M.D., H. A. Quigley, M.D., J. M. Gass, M.D., Archives of Ophthalmology, Vol. 96, December 1978.

"Histopathologic Evaluation of Adhesive Properties of Early Lesions in Cryopexy and Diathermy," J.O. Sipperley, M.D., R. Machemer, M.D., International Ophthalmology, Vol. 3, 1981.

"Septic Retinal Cyst in Endogenous Klebsiellaendophthalmitis," J. O. Sipperley, M.D., J. W. Shore, M.D., American Journal of Ophthalmology, Vol. 945, July 1982.

"Intraocular Foreign Body From A Nylon Line Grass Trimmer," H. M. Lambert, M.D., J. O. Sipperley, M.D., Annals of Ophthalmology, Vol. 15, No. 10, Pg. 936, 1983

"Autosomal Dominant Preretinal Vascular Loops," H. M. Lambert, M. D., J. O. Sipperley, M.D., D.E. Shacklett, M.D., Retina, Vol. 3, Pg. 258, 1984.

"A Prone Bed," B. Miller, R.N., R. G. Chenowith, M.D., J. O. Sipperley, M.D. American Journal of Ophthalmology, Vol. 97, Pg. 787-788, June 1984.

"Two Years Course of Visual Acuity in Severe Proliferative Diabetic Retinopathy with Conventional Management," DRVS Report #1, The DRVS Research Group, Ophthalmology, Vol. 92, 492-502, April 1985.

"Air Travel and Intraocular Gas," Dieckert, J., O'Connor, P., Schaklett, D., Tredici, T., Lambert, H., Fanton, D., Sipperley, J., Rasahid, E., Ophthalmology, Vol. 93, 642-645, May 1986.

"Early Vitrectomy for Severe Vitreous Hemorrhage in Diabetic Retinopathy," DRVS Report #2, Archives of Ophthalmology, Vol. 103, 1644 - 1652, November, 1986.

"Photocoagulation for Diabetic Macular Edema," ETDRS Report #1, ETDRS Study Group, Archives of Ophthalmology, Vol. 103, 1796 - 1806, December 1985.

"Linear Nevus Sebaceous Syndrome," Lambert, H., Sipperley, J., Shore, J., Dieckert, J., Evans, R., Lowd, D. Ophthalmology, Vol. 94, 278 - 282, March 1987.

"The Management of Subretinal Gas Following Attempted Pneumatic Retinal Reattachment," McDonald, H. R., AbramG. W., Irvine, A. R., Sipperley, J. O. , Boyden, B. S., Flore, J. V., Jr., Zegarra, H., Ophthalmology, Vol. 94(4), 319-26, April 1987.

- "Anterior Hyaloidal Fibrovascular Proliferation after Diabetic Vitrectomy"(letter), R.V. Campo,M.D., J.O. Sipperley, M. D., American Journal of Ophthalmology, Vol. 105:432 – 434, April, 1988.
- 'Medjorje Maculopathy,"(letter), R.V. Campo M.D., J.O. Sipperley, M.D., G. Hall, M.D., J.A. Rappazzo, M.D., New England Journal of Medicine, vol. 318: 1207, May 1988.
- "Vitrectomy for Epiretinal Membrane with Candida Chorioretinitis," H.R. McDonald, M.D., S. Debustros, M.D., J.O. Sipperley, M.D., Ophthalmology, Vol. 97: 466 – 469, April 1990
- "Vitreous Surgery for Retinal Detachment Associated with Choroidal Coloboma, McDonald, H. R., Lewis, H., Brown, G., S. Sipperley, J. O., Archives of Ophthalmology, Vol. 109-1, 1399 - 402, October 1991.
- "A Comparison of Retrobulbar Versus Sub-Tenons Corticosteroid Therapy for Cystoid Macular Edema refractory to Topical Medications," A.B. Thach, M.D., P.U. Dugel, M.D., R.J. Flindal, M.D., J.O. Sipperley, M.D., S.R. Sneed, M.D., Ophthalmology, Vol. 104: 2003-2008, December 1997.
- 'Outcomes of Vitreoretinal surgery in Patients with X-linked Retinoschisis," P.J. Rosenfeld, M.D., H.W. Flynn Jr., M.D., H.R. McDonald, M.D., P.E. Rubsamen, M.D., W.E. Smiddy, M.D., J.O. Sipperley, M.D., I. Boniuk, M.D., A.J. Packer, M.D., Ophthalmic Surgery and Lasers, Vol. 29(3): 190 – 197, March 1998
- "Ocular injuries from paintball pellets," A.B. Thach, T.P. Ward, P.U. Dugel, J.O.Sipperley, et.al. Ophthalmology, Vol 106(3) March 1999.
- "Macular hole surgery with internal limiting membrane peeling and intravitreal air," D.W.Park, J.O.Sipperley, S.R.Sneed, P.U.Dugel, J.Jacobsen, Ophthalmology, Vol 106(7), July 1999.
- "Pars plana vitrectomy without sclera buckle for pseudophakic retinal detachments," R.V.Campo, J.O.Sipperley, S.R.Sneed, D.W.Park, P.U.Dugel,J.Jacobsen, R.J.Flindall, Ophthalmology, Vol 106(9), Sep 1999.
- "Outcome of sulcus fixation of dislocated PC IOL's using temporary externalization of the haptics," A.B.Thach, P.U.Dugel,et.al, Ophthalmology, Vol 107(3), Mar 2000
- "Progressive subretinal fibrosis and blindness associated with multifocal granulomatous chorioretinitis: A variant of sympathetic ophthalmia," R.C.Wang, E. Zamir, P.U.Dugel, J.O.Sipperley, Ophthalmology, Vol109(8), Aug 2002.
- "Macular pucker removal with and without ILM peeling: pilot study,"D.W.Park, P.U.Dugel, J.Garda, J.O.Sipperley , et al.Ophthalmology, Vol 110(1), Jan 2003.
- "Large spot size TTT for the treatment of occult SRN associated with AMD", A.B.Thach, J.O.Sipperley, P.U.Dugel, S.R.Sneed, D.W.Park, J Cornelius, Arch Ophthalmol,Vol 121(6), June 2003.
- "Surgery for subfoveal choroidal neovascularization: Report #1 - #12, SST study group, Ophthalmology, 2003 – 2006.